As the company continues to chart its course through clinical trials and regulatory scrutiny, the scientific and medical communities will be keenly observing the future developments surrounding Ixo-vec. With wet AMD affecting millions globally, the stakes for both patient outcomes and corporate success have never been higher. Adverum?s advancements herald a new era in ocular therapeutics, promising a glimmer of hope for patients facing the debilitating effects of this condition.